Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
|ClinicalTrials.gov Identifier: NCT01124019|
Recruitment Status : Completed
First Posted : May 14, 2010
Last Update Posted : October 13, 2014
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1600 participants|
|Official Title:||SNP Panels and Risk Assessment in Women Undergoing Mammography|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
A random sample of 600 women undergoing screening mammography
BIRADS score of 4
An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
- Predicted Risk Category and Prevention RecommendationsThe predicted risk category and prevention recommendations which are based upon the category each patient falls into after risk assessment using either a traditional or a SNP-based approach. Change in PPV of mannographic biopsy by stratification into low and high risk groups.
- Tests and EvaluationsSecondary Outcome will be determining the number of women who are ordered and/or complete tests and/or evaluations if there are abnormal imaging results during mammography or if they have high lifetime risk. These will be measured through access to the electronic medical records (EMR) and/or through a follow up survey.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01124019
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Susan Domchek, MD||Abramson Cancer Center of the University of Pennsylvania|